FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897427196> ?p ?o ?g. }

• W2897427196 endingPage "S83" @default.
• W2897427196 startingPage "S83" @default.
• W2897427196 abstract "Approximately 30-40% of cervical cancer patients treated with radio(chemo)therapy (RTCT) develop recurrence that can be difficult to treat. New approaches for overcoming treatment failures are needed. The CXCL12/CXCR4 chemokine pathway promotes tumor growth and metastasis in various tumor sites and we have observed the pathway is upregulated in RT treated cervical cancers. Plerixafor, an inhibitor of this pathway, is approved clinically and our initial studies showed the addition of plerixafor to RTCT enhanced primary tumor response. The current studies examined: 1. Different ways of sequencing RTCT and plerixafor to maximize efficacy 2. Biomarkers of response to RTCT and plerixafor 3. Effects of plerixafor with RTCT on intestinal toxicity, an important dose-limiting consequence of treatment in these patients. Orthotopic cervix xenografts were treated with RT (30 Gy; 2 Gy/day) and weekly cisplatin (4mg/kg) with or without plerixafor (5mg/kg/day). Plerixafor was administered concurrently with RTCT (3 wks), adjuvantly after RTCT (3 wks) or continuously (6 wks). Biomarker response was evaluated at the end of the concurrent and adjuvant treatments. Tumor growth delay was assessed at later times. Tumor control was assessed after 50 Gy (2Gy/day-5 wks) with cisplatin and plerixafor. Late intestinal toxicity was assessed by histologic examination of the colorectal junction 90 days after treatment. Plerixafor, whether administered concurrently or adjuvantly, prolonged tumor growth delay following RTCT (30 Gy). Adjuvant plerixafor was associated with longer growth delay. Tumor cure was achieved at a higher RT dose of 50 Gy with RTCT+plerixafor. RTCT alone increased CXCL12/CXCR4 signalling, PD-L1 (immune checkpoint marker) expression and the tumor accumulation of myeloid cells. The addition of plerixafor during or after RTCT abrogated these effects. This suggests: 1) RTCT upregulation of the CXCL12/CXCR4 pathway leads to recruitment of immune populations into the tumor that confer treatment resistance and 2) RTCT-induced increases in PD-L1 expression may promote an immunosuppressed tumor microenvironment that impairs treatment response. Plerixafor reduced RT-related intestinal injury, suggesting a protective effect that may relate to modifications of immune cell infiltrates involved with the mobilization of mesenchymal stem cells from the marrow. Further investigation is needed to assess mechanisms underlying these radio-protective effects. Adding plerixafor to RTCT blunts RTCT-induced upregulation of the CXCL12/CXCR4 pathway and reduces the increase in tumor-associated myeloid cells. These benefits may apply to other tumors where RT plays a curative role. Plerixafor protects normal tissue from RT injury. Few if any drugs have been identified previously that both improve the effectiveness of RT and prevent side effects. The combination of RT and plerixafor warrants testing in clinical trials to validate these findings." @default.
• W2897427196 created "2018-10-26" @default.
• W2897427196 creator A5031467567 @default.
• W2897427196 creator A5034829322 @default.
• W2897427196 creator A5039191328 @default.
• W2897427196 creator A5044339155 @default.
• W2897427196 creator A5051752063 @default.
• W2897427196 creator A5056397477 @default.
• W2897427196 creator A5064900626 @default.
• W2897427196 creator A5077793054 @default.
• W2897427196 date "2018-11-01" @default.
• W2897427196 modified "2023-10-18" @default.
• W2897427196 title "Molecular Targeting to Expand the Therapeutic Ratio in Women with Curable Cervical Cancer" @default.
• W2897427196 doi "https://doi.org/10.1016/j.ijrobp.2018.06.220" @default.
• W2897427196 hasPublicationYear "2018" @default.
• W2897427196 type Work @default.
• W2897427196 sameAs 2897427196 @default.
• W2897427196 citedByCount "0" @default.
• W2897427196 crossrefType "journal-article" @default.
• W2897427196 hasAuthorship W2897427196A5031467567 @default.
• W2897427196 hasAuthorship W2897427196A5034829322 @default.
• W2897427196 hasAuthorship W2897427196A5039191328 @default.
• W2897427196 hasAuthorship W2897427196A5044339155 @default.
• W2897427196 hasAuthorship W2897427196A5051752063 @default.
• W2897427196 hasAuthorship W2897427196A5056397477 @default.
• W2897427196 hasAuthorship W2897427196A5064900626 @default.
• W2897427196 hasAuthorship W2897427196A5077793054 @default.
• W2897427196 hasConcept C121608353 @default.
• W2897427196 hasConcept C126322002 @default.
• W2897427196 hasConcept C126894567 @default.
• W2897427196 hasConcept C129470790 @default.
• W2897427196 hasConcept C13373296 @default.
• W2897427196 hasConcept C143998085 @default.
• W2897427196 hasConcept C2776694085 @default.
• W2897427196 hasConcept C2776914184 @default.
• W2897427196 hasConcept C2777863537 @default.
• W2897427196 hasConcept C2778220009 @default.
• W2897427196 hasConcept C2778239845 @default.
• W2897427196 hasConcept C2778828106 @default.
• W2897427196 hasConcept C2780435969 @default.
• W2897427196 hasConcept C526805850 @default.
• W2897427196 hasConcept C71924100 @default.
• W2897427196 hasConceptScore W2897427196C121608353 @default.
• W2897427196 hasConceptScore W2897427196C126322002 @default.
• W2897427196 hasConceptScore W2897427196C126894567 @default.
• W2897427196 hasConceptScore W2897427196C129470790 @default.
• W2897427196 hasConceptScore W2897427196C13373296 @default.
• W2897427196 hasConceptScore W2897427196C143998085 @default.
• W2897427196 hasConceptScore W2897427196C2776694085 @default.
• W2897427196 hasConceptScore W2897427196C2776914184 @default.
• W2897427196 hasConceptScore W2897427196C2777863537 @default.
• W2897427196 hasConceptScore W2897427196C2778220009 @default.
• W2897427196 hasConceptScore W2897427196C2778239845 @default.
• W2897427196 hasConceptScore W2897427196C2778828106 @default.
• W2897427196 hasConceptScore W2897427196C2780435969 @default.
• W2897427196 hasConceptScore W2897427196C526805850 @default.
• W2897427196 hasConceptScore W2897427196C71924100 @default.
• W2897427196 hasIssue "3" @default.
• W2897427196 hasLocation W28974271961 @default.
• W2897427196 hasOpenAccess W2897427196 @default.
• W2897427196 hasPrimaryLocation W28974271961 @default.
• W2897427196 hasRelatedWork W1538158307 @default.
• W2897427196 hasRelatedWork W2026372288 @default.
• W2897427196 hasRelatedWork W2099838903 @default.
• W2897427196 hasRelatedWork W2325196866 @default.
• W2897427196 hasRelatedWork W2348310476 @default.
• W2897427196 hasRelatedWork W2411229286 @default.
• W2897427196 hasRelatedWork W2589832443 @default.
• W2897427196 hasRelatedWork W363598932 @default.
• W2897427196 hasRelatedWork W4237549452 @default.
• W2897427196 hasRelatedWork W4243635653 @default.
• W2897427196 hasVolume "102" @default.
• W2897427196 isParatext "false" @default.
• W2897427196 isRetracted "false" @default.
• W2897427196 magId "2897427196" @default.
• W2897427196 workType "article" @default.